Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives $20.83 Average PT from Analysts

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) have been given an average recommendation of "Buy" by the eight analysts that are covering the company, Marketbeat reports. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $20.83.

A number of analysts have recently commented on the company. Guggenheim began coverage on Zevra Therapeutics in a research note on Monday, October 7th. They set a "buy" rating and a $20.00 price target on the stock. HC Wainwright reissued a "buy" rating and set a $20.00 target price on shares of Zevra Therapeutics in a report on Monday, September 30th. JMP Securities initiated coverage on shares of Zevra Therapeutics in a research note on Tuesday, September 24th. They set an "outperform" rating and a $17.00 price target for the company. William Blair raised shares of Zevra Therapeutics to a "strong-buy" rating in a research note on Friday, August 30th. Finally, Canaccord Genuity Group lowered their target price on Zevra Therapeutics from $24.00 to $22.00 and set a "buy" rating for the company in a research report on Wednesday, September 18th.

Zevra Therapeutics Price Performance

Shares of ZVRA stock traded up $0.14 on Thursday, hitting $8.95. 212,613 shares of the company's stock were exchanged, compared to its average volume of 535,372. Zevra Therapeutics has a 12 month low of $3.89 and a 12 month high of $9.00. The company has a debt-to-equity ratio of 1.80, a current ratio of 2.00 and a quick ratio of 2.00. The company has a 50 day moving average of $7.83 and a 200 day moving average of $6.29. The stock has a market cap of $470.93 million, a P/E ratio of -5.24 and a beta of 1.93.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last issued its earnings results on Tuesday, August 13th. The company reported ($0.48) earnings per share for the quarter, missing analysts' consensus estimates of ($0.47) by ($0.01). Zevra Therapeutics had a negative net margin of 274.10% and a negative return on equity of 124.85%. The company had revenue of $4.45 million during the quarter, compared to analyst estimates of $4.08 million. During the same quarter in the prior year, the business earned ($0.15) EPS. On average, equities research analysts predict that Zevra Therapeutics will post -1.63 EPS for the current year.

Institutional Investors Weigh In On Zevra Therapeutics

Institutional investors have recently made changes to their positions in the stock. International Assets Investment Management LLC lifted its position in shares of Zevra Therapeutics by 594.0% during the 3rd quarter. International Assets Investment Management LLC now owns 6,940 shares of the company's stock valued at $48,000 after acquiring an additional 5,940 shares during the period. Price T Rowe Associates Inc. MD bought a new position in shares of Zevra Therapeutics during the 1st quarter worth about $64,000. Hunter Associates Investment Management LLC acquired a new stake in shares of Zevra Therapeutics in the 3rd quarter valued at about $92,000. SG Americas Securities LLC acquired a new stake in shares of Zevra Therapeutics in the 3rd quarter valued at about $105,000. Finally, City State Bank increased its position in Zevra Therapeutics by 14.1% in the 3rd quarter. City State Bank now owns 16,224 shares of the company's stock valued at $113,000 after buying an additional 2,000 shares in the last quarter. Institutional investors own 35.03% of the company's stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.